Biosimilars Market 2026 | Biologic Drug Access & Pharmaceutical Market Growth, FDA Approvals 2026, Regulatory Approvals (2025-2026)

DataM Intelligence has released a new research report titled "Biosimilars Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Biosimilars market.

North America dominates the global biosimilars market, accounting for the highest revenue share of 33.87% in 2025.

The oncology segment dominated the global biosimilars market by therapeutic area, accounting for the largest revenue share of 55.71% in 2025.

Get a Market Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/biosimilars-market?kb

United States: Recent Industry Developments

✅ February 2026: Amgen expanded its biosimilars portfolio in the United States with increased commercialization initiatives for oncology and immunology biosimilars to improve treatment affordability.

✅ January 2026: Pfizer strengthened its biosimilar manufacturing capabilities to support growing demand for cost-effective biologic therapies across hospital and specialty care settings.

✅ December 2025: Biocon Biologics accelerated U.S. market penetration through strategic partnerships and expanded distribution of insulin and oncology biosimilar products.

List of Key Players 2026:

Pfizer Inc., Amgen Inc., Novartis AG (Sandoz division), Samsung Bioepis Co., Ltd., and Celltrion, Inc. leading in monoclonal antibody and oncology biosimilars. Companies including Biocon Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., and Dr. Reddy's Laboratories Ltd

European companies such as STADA Arzneimittel AG and Fresenius Kabi AG are capitalizing on strong regional distribution networks and hospital-focused product portfolios, while major players including Boehringer Ingelheim International GmbH, Merck KGaA, and F. Hoffmann-La Roche Ltd. continue to strengthen their presence through innovation and strategic collaborations.

Growth Forecast Projected 2026:

The Global Biosimilars Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Latest FDA Approvals (2025-2026):

• January 2026: Filkri (filgrastim-laha) approved as a biosimilar for Neupogen to treat neutropenia in cancer patients.

• December 2025: Boncresa and Oziltus (denosumab-mobz) approved as biosimilars referencing Prolia and Xgeva for osteoporosis and bone-related conditions.

• December 2025: Nufymco (ranibizumab-leyk) approved as a biosimilar to Lucentis for retinal diseases such as macular degeneration.

• November 2025: Armlupeg (pegfilgrastim-unne) approved as a biosimilar referencing Neulasta for reducing infection risk during chemotherapy.

• November 2025: Poherdy (pertuzumab-dpzb) approved as a biosimilar to Perjeta for HER2-positive breast cancer treatment.

• October 2025: Osvyrti and Jubereq (denosumab-desu) approved as biosimilars referencing Prolia/Xgeva for bone health and cancer-related bone loss.

• October 2025: Eydenzelt (aflibercept-boav) approved as a biosimilar to Eylea for retinal vascular disorders.

• September 2025: Enoby and Xtrenbo (denosumab-qbde) approved as biosimilars referencing Prolia and Xgeva.

• March 2025: Omlyclo (omalizumab-igec) approved as a biosimilar to Xolair for allergic asthma and chronic urticaria.

• January 2025: Avtozma (tocilizumab-anoh) approved as a biosimilar referencing Actemra for autoimmune diseases such as rheumatoid arthritis.

Key Developments 2025-2026:

✅ February 2026: Pharmaceutical companies accelerated development and commercialization of biosimilars targeting high-value biologic drugs, expanding treatment accessibility for oncology, autoimmune, and chronic disease therapies.

✅ January 2026: Biopharmaceutical manufacturers strengthened production capabilities by investing in advanced biologics manufacturing facilities to support large-scale biosimilar development and global distribution.

✅ December 2025: Healthcare providers increased biosimilar adoption as regulatory authorities expanded approval pathways and encouraged substitution policies to reduce biologic therapy costs.

✅ November 2025: Strategic collaborations between biotechnology firms and contract development and manufacturing organizations (CDMOs) supported faster biosimilar product development and regulatory submissions.

✅ October 2025: Companies expanded biosimilar portfolios through pipeline development focusing

How Our Market Research Process Works:

The global Biosimilars Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the Biosimilars ecosystem.

Recent Mergers & Acquisitions (M & A):

• February 2026: USV Pvt. Ltd. announced a ₹1,600 crore acquisition of a pharmaceutical asset to strengthen its biologics and biosimilar portfolio expansion strategy.

• December 2025: Intas Pharmaceuticals acquired the UDENYCA (pegfilgrastim) biosimilar from Coherus BioSciences for approximately $558 million, strengthening its oncology biosimilars portfolio.

• 2025: Biocon Biologics completed the acquisition and integration of Viatris' global biosimilars business, gaining control of 20+ biosimilar assets and commercialization rights in over 70 countries.

• January 2025: Teva Pharmaceutical Industries entered a commercialization partnership with Samsung Bioepis for the EPYSQLI (eculizumab) biosimilar in the United States market.

• 2025: Dr. Reddy's Laboratories formed a commercial collaboration with Alvotech to develop and commercialize a denosumab biosimilar, expanding its biologics pipeline.

• 2025: Cipla partnered with Tanvex BioPharma for the development and commercialization of a filgrastim biosimilar, targeting global oncology supportive-care markets.

Request Strategic Market Customization: https://datamintelligence.com/customize/biosimilars-market?kb

Japan: Recent Industry Developments

✅ February 2026: Fujifilm Kyowa Kirin Biologics advanced large-scale manufacturing technologies for monoclonal antibody biosimilars to support Japan's expanding biologics market.

✅ January 2026: Daiichi Sankyo expanded development programs for oncology biosimilars aimed at improving access to biologic cancer treatments.

✅ December 2025: Nichi-Iko Pharmaceutical strengthened collaborations with global biotech companies to introduce new biosimilar therapies in the Japanese healthcare market.

Major Focused Key Segmentations 2026:

By Drug Class: Monoclonal Antibodies, Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors, Granulocyte Colony-Stimulating Factor, Insulin, Erythropoietin, Human Growth Hormone, Follitropin, Interferons, Anti-Vascular Endothelial Growth Factor, and Other

By Therapeutic Area: Oncology, Immunology & Autoimmune Diseases, Metabolic Diseases (including diabetes), Neurology, Infectious Diseases, Rare Diseases, and Others

By Manufacturing Modality: Mammalian Cell-Based Biosimilars, Microbial-Based Manufacturing, Plasma-Derived Manufacturing, and Other Manufacturing Platforms

By Route of Administration: Intravenous, Subcutaneous, Intramuscular, and Others

By End-User: Hospitals & Specialty Clinics, Infusion Centers, Specialty Pharmacies, and Others

Regional Growth Analysis for Market:

North America (U.S.)

⇥ FDA approved 19 biosimilars in 2024, signaling faster regulatory pathways, while 38+ applications remain under review globally targeting U.S. approvals; biosimilars have generated tens of billions of dollars in healthcare savings, accelerating payer adoption.

Europe

⇥ EMA has approved over 55 biosimilars since the market's early phase, creating one of the most mature regulatory ecosystems, with strong tender systems and high substitution rates in oncology and anti-TNF therapies.

Asia-Pacific (China, India, South Korea)

⇥ Regional regulators introduced biosimilar development guidelines and accelerated review pathways, while expanding biologics manufacturing capacity to supply both domestic markets and regulated global markets.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=biosimilars-market?kb

Biosimilars - Regulatory Affairs (2025-2026)

• 2026: The FDA introduced additional draft guidance to streamline pharmacokinetic study requirements and allow use of foreign clinical data in certain cases to accelerate biosimilar development.

• 2026: Regulatory agencies globally continued strengthening pharmacovigilance and post-marketing surveillance requirements to monitor immunogenicity and long-term safety of biosimilars.

• October 2025: The U.S. Food and Drug Administration released draft guidance to simplify biosimilar development by reducing unnecessary comparative clinical trials and focusing more on analytical and pharmacokinetic data.

• November 2025: Updated regulatory recommendations emphasized advanced analytical testing to demonstrate biosimilarity, helping shorten development timelines and reduce R&D costs for biosimilar manufacturers.

• 2025: Regulators increasingly moved away from mandatory comparative efficacy studies, enabling faster biosimilar approvals while maintaining safety and efficacy standards.

Biosimilars - Government Policies (2025-2026)

• United States (2025-2026): Federal health authorities proposed regulatory reforms to accelerate biosimilar approvals and increase competition in high-cost biologic drug markets.

• United States (2025): The U.S. government promoted biosimilar adoption through policy initiatives aimed at lowering biologic drug costs and expanding patient access to affordable therapies.

• European Union (2025): The European Medicines Agency reinforced policies recognizing biosimilars as scientifically interchangeable with reference biologics to improve clinical adoption across EU healthcare systems.

• India (2025): The Government of India initiated updated biosimilar regulatory guidelines to strengthen manufacturing standards and improve quality control in biologic drug development.

• Global Policy Trend (2026): Governments worldwide are encouraging biosimilar competition to address rising biologic drug costs and support healthcare sustainability.

FAQ

Q1: What is the current size of the Biosimilars Market?

A: The Biosimilars Market was valued at US$30.30 Billion in 2024, projectd to Growth US$ 34.57 Billion in 2025 and is forecasted to hit US$99.3 Billion by 2033

Q2: How rapidly will the Market expanding?

A: The Biosimilars market is projected to grow at a CAGR of 14.1% between 2026 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.